Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780233 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)
A Phase 1 study, sponsored by INSYS Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01780233 is a Phase 1 study that has completed, run by INSYS Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01780233, a Phase 1 study, has completed, sponsored by INSYS Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study was to compare the rate of absorption and bioavailability of fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, and fentanyl citrate injection 100 µg intravenously.
Interventions
- DRUG Fentanyl 400 µg sublingual spray
- DRUG Actiq® 400 µg transmucosally
- DRUG Fentanyl citrate injection 100 µg intravenously
- DRUG Naltrexone 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01780233
The ClinicalTrials.gov registry entry for NCT01780233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is INSYS Therapeutics, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fentanyl 400 µg sublingual spray is the first listed.
NCT01780233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01780233 about?
NCT01780233 is a clinical study titled "Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)". The objective of this study was to compare the rate of absorption and bioavailability of fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, and fentanyl citrate injection 100 µg intravenously.
What is the current status of trial NCT01780233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT01780233?
The interventions under investigation include: Fentanyl 400 µg sublingual spray (DRUG), Actiq® 400 µg transmucosally (DRUG), Fentanyl citrate injection 100 µg intravenously (DRUG), Naltrexone 50 mg (DRUG).
Who is sponsoring clinical trial NCT01780233?
This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.